{
    "nct_id": "NCT05456880",
    "official_title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises (Beacon Trial)",
    "inclusion_criteria": "Key Inclusion Criteria Include:\n\n1. Age ≥18 years to ≤35 years for the initial sentinel cohort; for subsequent enrollment patients from ≥12 years up to ≤35 years may be enrolled only upon approval by FDA.\n2. Documented diagnosis of sickle cell disease with βS/βS, βS/β0, or βS/β+ genotypes.\n3. Severe SCD defined by the occurrence of at least 4 severe VOCs in the 24 months prior to screening despite receiving hydroxyurea or other supportive care measures\n\nKey Exclusion Criteria Include:\n\n1. HbF levels >20%, obtained at the time of screening on or off hydroxyurea therapy\n2. Previous receipt of an autologous or allogeneic HSCT or solid organ transplantation\n3. Available and willing matched sibling donor\n4. Definitive diagnosis of moyamoya syndrome based on screening brain MRA\n5. History of overt stroke\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 35 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}